U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H27F2N5O3S2.C2H4O3
Molecular Weight 695.7594
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLESATINIB GLYCOLATE

SMILES

COCCNCc1ccc(-c2cc3c(c(ccn3)Oc4ccc(cc4F)N=C(N=C(Cc5ccc(cc5)F)O)S)s2)nc1.C(C(=O)O)O

InChI

InChIKey=BOWRAZCFCCNWMB-UHFFFAOYSA-N
InChI=1S/C31H27F2N5O3S2.C2H4O3/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19;3-1-2(4)5/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42);3H,1H2,(H,4,5)

HIDE SMILES / InChI

Molecular Formula C2H4O3
Molecular Weight 76.0514
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C31H27F2N5O3S2
Molecular Weight 619.7079
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created using several sources including: http://www.generon.co.uk/amine-oxides-1830/mgcd-265--182002623.html | https://clinicaltrials.gov/ct2/show/NCT02544633

Glesatinib (MGCD265) is an orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Glesatinib binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs. Studies in a gastric cancer xenograft model revealed that, in addition to the typically reported cellular activities, glesatinib in combination with erlotinib disrupted the glycolysis pathway, suggesting a novel mechanism of action for this drug. Glesatinib has been studied in a variety of advanced solid tumors including NSCLC, as a monotherapy and in combination with either docetaxel or erlotinib. In an ongoing phase 1 study in patients with MET positive or AXL-rearranged advanced solid tumors, glesatinib demonstrated preliminary single-agent activity, with all three patients with MET dysregulated NSCLC (two with METex14 alterations and one with increased GCN) showing significant tumor regression at the first assessment. A phase 2 study is currently recruiting patients with MET-dysregulated (mutated or amplified) advanced or metastatic NSCLC.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P08581
Gene ID: 4233.0
Gene Symbol: MET
Target Organism: Homo sapiens (Human)
1.0 nM [IC50]
3.0 nM [IC50]
3.0 nM [IC50]
4.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
2017 Jan
Patents

Sample Use Guides

MGCD265 (glesatinib) was given orally from 24 mg/m2 daily to 235 mg/m2 twice daily uninterrupted to patients with advanced solid malignancy until disease progression
Route of Administration: Oral
In MKN45 cells the IC50 value of glesatinib was 20 nM
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:32:00 UTC 2021
Edited
by admin
on Sat Jun 26 15:32:00 UTC 2021
Record UNII
517V126QMT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLESATINIB GLYCOLATE
Common Name English
MGCD-265 GLYCOLATE
Code English
Code System Code Type Description
FDA UNII
517V126QMT
Created by admin on Sat Jun 26 15:32:00 UTC 2021 , Edited by admin on Sat Jun 26 15:32:00 UTC 2021
PRIMARY
PUBCHEM
91886000
Created by admin on Sat Jun 26 15:32:00 UTC 2021 , Edited by admin on Sat Jun 26 15:32:00 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY